Archana Jarathi, MD
Endocrinology, Diabetes & Metabolism · Little Rock, ARNPI 1487801056
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 459 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 9.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,833 and has fallen 61.5% since, to $705 in 2025.
Across 459 payments — averaging $15.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$716
- Abbott$680
- Sanofi-aventis U.S. LLC$675
- Lilly USA, LLC$674
- Dexcom, Inc.$602
- Boehringer Ingelheim$497
- plus $3K from 31 others
What the payments were for
- Food & beverage$7,227100%
- Education$350%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 58 | $716 |
| Abbott | 42 | $680 |
| Sanofi-aventis U.S. LLC | 45 | $675 |
| Lilly USA, LLC | 39 | $674 |
| Dexcom, Inc. | 36 | $602 |
| Boehringer Ingelheim | 32 | $497 |
| Amgen | 26 | $424 |
| Insulet Corporation | 22 | $335 |
| AbbVie | 19 | $328 |
| Bayer | 16 | $308 |
| Merck | 15 | $284 |
| Xeris Pharmaceuticals, Inc. | 14 | $264 |
| AstraZeneca | 16 | $254 |
| Johnson & Johnson | 20 | $209 |
| Corcept Therapeutics | 9 | $170 |
| Tandem Diabetes Care, Inc. | 6 | $95 |
| Nevro Corp. | 5 | $82 |
| Neurocrine Biosciences, Inc. | 3 | $63 |
| Valeritas, Inc. | 3 | $62 |
| Acella Pharmaceuticals, LLC | 3 | $57 |
| BETA Bionics, Inc. | 3 | $56 |
| Regeneron Healthcare Solutions, Inc. | 3 | $48 |
| Medtronic | 3 | $48 |
| Pfizer | 3 | $47 |
| Recordati_rare_diseases_inc. | 4 | $46 |
| Cequr Corporation | 1 | $34 |
| Esperion Therapeutics, Inc. | 2 | $26 |
| EUSA Pharma (US) LLC | 2 | $25 |
| Averitas Pharma Inc. | 1 | $25 |
| IBSA Pharma Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Ascensia Diabetes Care US Inc. | 1 | $19 |
| Zealand Pharma US, Inc. | 1 | $16 |
| Ascendis Pharma Endocrinology Inc | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Lifescan, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STEGLATRO$100
How this compares
$7,263 in reported general payments places this provider in the 55th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.
See all endocrinology, diabetes & metabolism providers in Arkansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 437 | $582,447 |
| JardianceEmpagliflozin | 351 | $299,296 |
| MounjaroTirzepatide | 199 | $226,146 |
| TrulicityDulaglutide | 107 | $128,947 |
| Tresiba Flextouch U-200Insulin Degludec | 96 | $104,249 |
| Tresiba Flextouch U-100Insulin Degludec | 85 | $72,587 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $58,571 |
| JanuviaSitagliptin Phosphate | 57 | $52,155 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 84 | $47,504 |
| FarxigaDapagliflozin Propanediol | 42 | $36,359 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $35,420 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 42 | $33,066 |
| Novolog FlexpenInsulin Aspart | 105 | $28,694 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 56 | $18,676 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 19 | $17,944 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $716 | $591,549473 claims |
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $674 | $357,331334 claims |
| Boehringer IngelheimJardiance, Tradjenta | $497 | $304,543363 claims |
| MerckJanuvia, Janumet Xr, Janumet | $284 | $93,476114 claims |
| AstraZenecaFarxiga | $254 | $36,35942 claims |
| BayerKerendia | $308 | $12,04114 claims |
| AbbVieSynthroid | $328 | $11,619150 claims |
| Sanofi-aventis U.S. LLCLantus | $675 | $1,98311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.
Other endocrinology, diabetes & metabolism in Little Rock
- Richard GriffithsLittle Rock$925K
- James ThrasherLittle Rock$349K
- Richard RappLittle Rock$47K
- Shunzhong BaoLittle Rock$40K
- Teresa NimmoLittle Rock$29K
- Madhu BudhrajaLittle Rock$29K
- Joseph HenskeLittle Rock$23K
- Nidhi JainLittle Rock$9K
- Allen ReddingLittle Rock$7K
- Zulekha HamidLittle Rock$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.